Skip to main content

Table 1 Characteristics of patients treated for vulvar squamous cell carcinoma (vSCC) from January 2006 to December 2016 (AWD, alive with the disease; DOD, dead of disease; DOID, dead of intercurrent disease; NED, no evidence of disease)

From: Indocyanine green fluorescence imaging, sentinel lymph node mapping in patients with vulvar cancer: peritumoral injection dosage and waiting times in our experience

Variables (n = 165)
Age median (years) (range) 71 (34–94)
Stage (FIGO 2009) (%)
 IA 29 (17.6)
 IB 63 (38.2)
 II 24 (14.5)
 IIIA 19 (11.5)
 IIIB 14 (8.5)
 IIIC 15 (9.1)
 IV 1 (0.6)
Tumor size (mm) (range) 40 (17–140)
Surgery (%)
 Radical local excision 11 (6.7)
 Radical vulvectomy 49 (29.7)
 Radical vulvectomy + LN dissection 105 (63.6)
 Radical vulvectomy + RT 60 (36.4)
 Radical vulvectomy + LN dissection + RT 52 (31.5)
Recurrence site (%)
 Local 29 (17.6)
 Regional 11 (6.7)
 Local-regional + distant 4 (2.4)
 Distant 1 (0.6)
Prognosis
 NED 84 (50.9)
 AWD 17 (10.3)
 DOD 39 (23.6)
 DOID 25 (15.2)
 Follow-up period (months) 85 (10–156)